Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9682990 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL4889683 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL30238199 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL29261872 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL24821261 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL350989 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL29669502 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL5188827 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL6368716 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10GAAHPGD | |
| SCHEMBL3763664 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114868614-A | Method for preserving potentilla anserina germplasm resources in field | 青海民族大学 | 2022-08-09 | — | — | CN | disclosed |
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| CN-101622241-B | Benzimidazole compound and medical application thereof | MITSUBISHI TANABE PHARMA CORP | 2013-05-22 | — | — | CN | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| CN-101622241-A | Benzimidazole compound and medical application thereof | MITSUBISHI TANABE PHARMA CORP | 2010-01-06 | — | — | CN | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | KDM4E 3547/4885ALDH1A1 63/4885HSD17B10 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.